Sánchez-MachÃn, I.; González-Pérez, R.; Mederos-Luis, E.; GarcÃa-Gil, S.; Poza-Guedes, P.
Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases. Allergies 2025, 5, 3.
https://doi.org/10.3390/allergies5010003
AMA Style
Sánchez-MachÃn I, González-Pérez R, Mederos-Luis E, GarcÃa-Gil S, Poza-Guedes P.
Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases. Allergies. 2025; 5(1):3.
https://doi.org/10.3390/allergies5010003
Chicago/Turabian Style
Sánchez-MachÃn, Inmaculada, Ruperto González-Pérez, Elena Mederos-Luis, Sara GarcÃa-Gil, and Paloma Poza-Guedes.
2025. "Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases" Allergies 5, no. 1: 3.
https://doi.org/10.3390/allergies5010003
APA Style
Sánchez-MachÃn, I., González-Pérez, R., Mederos-Luis, E., GarcÃa-Gil, S., & Poza-Guedes, P.
(2025). Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases. Allergies, 5(1), 3.
https://doi.org/10.3390/allergies5010003